HomeAI · summaries
Storia in 2 fonti
Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi
The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B
The FDA has expanded approval for marstacimab-hncq, which can now be given as routine prophylaxis for all individuals aged 6 years and older with hemophilia A or B, with or…
- ·
fiercepharma.com
Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi
The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A…